Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration Compared

Bluming, Avrum Z.

doi:10.7326/0003-4819-76-3-405

Cited by 139 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Divergent results have been obtained with the use of different preparations of BCG in these studies [8][9][10][11][12][13][14], and differing effects have also been noted in animal experiments [4], It has not been clear in the human studies whether the discrepancies seen have been due to the number of organisms injected, or to some intrinsic property of the strain and preparation used. Mathe et al [10,13] have shown that immunotherapy with BCG (Pasteur strain) given to patients with acute lymphoblastic leukemia in remission, prolongs remission duration compared to chemo therapy alone.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Adjuvant Effect of Three BCG Preparations in Mice

Baker¹,

Taub²

1978

Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the Adjuvant Effect of Three BCG Preparations in Mice

Baker¹,

Taub²

1978

Oncology

View full text Add to dashboard Cite

show abstract

“…Bluming et al (1972) have reported that BCG therapy by dermal scarification had a nonspecific potentiating effect on development of contact sensitivity to picryl chloride and on the recall of skin test reactivity to other skin test antigens which was not seen when lower doses of BCG were given by intradermal inoculation. No change in peripheral lymphocyte levels was noted.…”

Section: Effect Of Bog Therapymentioning

confidence: 99%

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy

Lui¹,

Karpuchas²,

Dent³

et al. 1975

Br J Cancer

View full text Add to dashboard Cite

Summary.-Cell mediated immunocompetence was measured serially in 35 patients with malignant melanoma in order to determine the effect of extent of disease and prognosis as well as the influence of BCG immunotherapy on immune reactivity.Compared with normal adult controls, statistically significant lymphopenia occurred only in patients with widespread disease. Seventeen of 21 patients with negative pre-therapy PPD skin test converted to skin test positivity. PHA blastogenesis was depressed only in patients in the pre-terminal stages of their disease using optimal mitogen concentrations for stimulation. Threshold concentrations of this mitogen more clearly demonstrated a depressed responsiveness which correlated in severity with extent of disease. PPD induced blastogenesis was normal or increased in the majority of patients; however, the degree of stimulation by PPD was less in the BCG induced convertors than in those patients who were skin test positive before BCG treatment. Comparison of the pre-and post BCG assessments reveals no significant differences except in relation to PPD conversion. We conclude that using threshold concentrations of PHA, impaired responses are regularly associated with disease beyond the regional lymph nodes. Routine assessment of lymphocyte function by these parameters did not provide information that was not available from clinical evaluation.

show abstract

“…The development of hypersensitivity reactions to extracts of autologous tumour and impaired immune reactions associated with the presence of large tumours further support the potential role of immune failure in the pathogenesis of BL. 6,7,8 . Clinical trials of immunotherapy were started in the early 1970's based on Burkitt's hypothesis of immunosurveilance using sera from patients who had undergone complete tumour regression, and immunostimulators like Bacillus Calmette Guerin (BCG) 9 .…”

Section: Introductionmentioning

confidence: 99%

Antibody and complement levels in patients with Burkitt's lymphoma

Umukoro

Onyesom

2006

Biokemistri

View full text Add to dashboard Cite

The concentration of immunoglobulins (IgA, IgG, and IgM) and complement (C 3 and C 4 ) were measured in fifty-seven (57) Nigerian children with Burkitt's lymphoma (BL), and in twenty-eight (28) apparently healthy control subjects, using the single radial immunodiffusion (SRID) (IgA, 330.11±260.55; IgG, 288.29 ± 346.95, IgM, 201.82 ± 64.132). Higher complement titres were also observed in the various clinical stages of BL C3 (stage:In=22, 177.25 ± 5172; stage II:n=11, 197.36 ± 65.40; stage III:n=20, 190.05 ± 60.91; stage IV:n = 4, 142.25 ± 81.40); C4 (stage I:n=22,288.68 ± 181.84, stage II:n=11, 207.91 ± 67.64; stage III:n=20,243.30 ± 164.70, stage IV:n=4, 331.75 ± 275.59). The complement values for control subjects were significantly lower than the BL patients; (C3:157.04± 37.76; C4 256.39 ± 181.93). These results show relative higher immnoglobulins and complement responses in Nigerian children with BL.

show abstract

Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration Compared

Cited by 139 publications

References 22 publications

Comparison of the Adjuvant Effect of Three BCG Preparations in Mice

Comparison of the Adjuvant Effect of Three BCG Preparations in Mice

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy

Antibody and complement levels in patients with Burkitt's lymphoma

Contact Info

Product

Resources

About